[go: up one dir, main page]

PL423203A1 - Growth factor to be applied in the anti-cancer therapy for patients with cancers, in which at least a part of cells shows the expression of EGFRvIII - Google Patents

Growth factor to be applied in the anti-cancer therapy for patients with cancers, in which at least a part of cells shows the expression of EGFRvIII

Info

Publication number
PL423203A1
PL423203A1 PL423203A PL42320317A PL423203A1 PL 423203 A1 PL423203 A1 PL 423203A1 PL 423203 A PL423203 A PL 423203A PL 42320317 A PL42320317 A PL 42320317A PL 423203 A1 PL423203 A1 PL 423203A1
Authority
PL
Poland
Prior art keywords
egfrviii
patients
cancers
expression
growth factor
Prior art date
Application number
PL423203A
Other languages
Polish (pl)
Other versions
PL238850B1 (en
Inventor
Piotr Rieske
Ewelina STOCZYŃSKA-FIDELUS
Sylwester Piaskowski
Andrzej Szczepan Wyrzykowski
Original Assignee
Calther Polska Spolka Z Ograniczona Odpowiedzialnoscia
Parsonather Spolka Z Ograniczona Odpowiedzialnoscia
Sylwester Piaskowski
Piotr Rieske
STOCZYNSKA FIDELUS Ewelina
Andrzej Szczepan Wyrzykowski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calther Polska Spolka Z Ograniczona Odpowiedzialnoscia, Parsonather Spolka Z Ograniczona Odpowiedzialnoscia, Sylwester Piaskowski, Piotr Rieske, STOCZYNSKA FIDELUS Ewelina, Andrzej Szczepan Wyrzykowski filed Critical Calther Polska Spolka Z Ograniczona Odpowiedzialnoscia
Priority to PL423203A priority Critical patent/PL238850B1/en
Priority to PCT/PL2018/000097 priority patent/WO2019078745A1/en
Priority to PL18867689.4T priority patent/PL3735261T3/en
Priority to EP18867689.4A priority patent/EP3735261B1/en
Publication of PL423203A1 publication Critical patent/PL423203A1/en
Publication of PL238850B1 publication Critical patent/PL238850B1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Niniejsze zgłoszenie dotyczy zastosowania TGFb w terapii chorób nowotworowych charakteryzujących się obecnością komórek nowotworowych wykazujących ekspresję EGFRvIII. Receptor EGFRvIII charakteryzuje się brakiem fragmentu białka kodowanego przez eksony 2-7 genu EGFR. Przedmiotem zgłoszenia jest zastosowanie TGFb w leczeniu pacjentów ze zmianami nowotworowymi, w przypadku których to zmian przynajmniej część komórek wykazuje ekspresje EGFRvIII.This application relates to the use of TGFb in the treatment of cancer characterized by the presence of EGFRvIII expressing cancer cells. The EGFRvIII receptor is characterized by the lack of a protein fragment encoded by exons 2-7 of the EGFR gene. The subject of the application is the use of TGFb in the treatment of patients with cancer, in which at least part of the cells express EGFRvIII.

PL423203A 2017-10-19 2017-10-19 Growth factor to be applied in the anti-cancer therapy for patients with cancers, in which at least a part of cells shows the expression of EGFRvIII PL238850B1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PL423203A PL238850B1 (en) 2017-10-19 2017-10-19 Growth factor to be applied in the anti-cancer therapy for patients with cancers, in which at least a part of cells shows the expression of EGFRvIII
PCT/PL2018/000097 WO2019078745A1 (en) 2017-10-19 2018-10-11 GROWTH FACTOR TGFβ1 OR TGFβ2 OR TGFβ3 FOR THE USE IN ANTICANCER THERAPY FOR PATIENTS WITH TUMORS, IN WHICH AT LEAST PART OF CELLS EXPRESS EGFRVIII
PL18867689.4T PL3735261T3 (en) 2017-10-19 2018-10-11 Growth factor tgfbeta1 or tgfbeta2 or tgfbeta3 for the use in anticancer therapy for patients with tumors, in which at least part of cells express egfrviii
EP18867689.4A EP3735261B1 (en) 2017-10-19 2018-10-11 Growth factor tgfbeta1 or tgfbeta2 or tgfbeta3 for the use in anticancer therapy for patients with tumors, in which at least part of cells express egfrviii

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL423203A PL238850B1 (en) 2017-10-19 2017-10-19 Growth factor to be applied in the anti-cancer therapy for patients with cancers, in which at least a part of cells shows the expression of EGFRvIII

Publications (2)

Publication Number Publication Date
PL423203A1 true PL423203A1 (en) 2019-04-23
PL238850B1 PL238850B1 (en) 2021-10-11

Family

ID=66167836

Family Applications (1)

Application Number Title Priority Date Filing Date
PL423203A PL238850B1 (en) 2017-10-19 2017-10-19 Growth factor to be applied in the anti-cancer therapy for patients with cancers, in which at least a part of cells shows the expression of EGFRvIII

Country Status (1)

Country Link
PL (1) PL238850B1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12015500807A1 (en) * 2012-11-09 2015-06-08 Centro Inmunologia Molecular Tgf�-derived polypeptides and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12015500807A1 (en) * 2012-11-09 2015-06-08 Centro Inmunologia Molecular Tgf�-derived polypeptides and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GALLO-OLLER, G., P144, A TRANSFORMING GROWTH FACTOR BETA INHIBITOR PEPTIDE, GENERATES ANTITUMOTAL EFFECTS AND MODIFIES SMAD7 AND SKI LEVELS IN HUMAN GLIBLASTOMA CELL LINES, 2016 *
NANA, A. W., OVERVIEW OF TRANSFORMING GROWTH FACTOR B SUPERFAMILY INVOLVEMENT IN GLIOBLASTOMA INITIATION AND PROGRESSION, 2015 *
SAMPSON, J. H., TUMOR-SPECIFIC LMMUNOTHERAPY TARGETING THE EGFRVLLL MUTATION IN PATIENTS WITH MALIGNANT GLIOMA, 2008 *

Also Published As

Publication number Publication date
PL238850B1 (en) 2021-10-11

Similar Documents

Publication Publication Date Title
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
PH12014502507A1 (en) Anti-angiogenesis therapy for the treatment of breast cancer
MX2021004881A (en) COMBINATION OF PALBOCICLIB AND RAD1901 FOR USE IN THE TREATMENT OF BREAST CANCER IN A SUBJECT WITH ESTROGEN RECEPTOR POSITIVE CANCER.
CL2016002359A1 (en) Antibodies that bind to human epidermal growth receptor (anti-egfr) and anti-egfr antibody and drug conjugates
ES2422605T3 (en) Antibody against klotho-beta for use in the treatment of tumors, cancer or cell proliferative disorders
PH12012502215A1 (en) Anti-fgfr2 antibodies
MY186977A (en) Tetrasubstituted alkene compounds and their use
EA201890272A1 (en) AXL-SPECIFIC CONJUGATES ANTIBODY AND MEDICINE FOR THE TREATMENT OF CANCER
MX343227B (en) ANTI-ERBB3 ANTIBODIES.
EA201300996A1 (en) USE OF EGFR FAMILY RECEPTOR INHIBITORS IN THE TREATMENT OF THE BREAST-GROWTH CANCER
MY204673A (en) Humanized anti-sirp antibodies
MX2015014046A (en) Drug combinations to treat cancer.
MX2020005640A (en) Humanized anti-liv1 antibodies for the treatment of breast cancer.
MX2016008072A (en) COMPOUNDS TO THE RECEIVER-3 OF THE FIBROPLAST GROWTH FACTOR (FGFR3) AND TREATMENT METHODS.
MX2019006331A (en) Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens.
MX2021012335A (en) HUMAN ANTIBODIES THAT BIND RET AND METHODS OF USE THEREOF.
MX2012001783A (en) Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone.
NZ607472A (en) Treatment for neoplastic diseases
MX2017011600A (en) Antibody therapeutics that bind psma.
HK1250626A1 (en) Combination treatments with seribantumab
EA201491352A1 (en) METHOD OF TREATMENT OF BREAST CANCER
MX2020005473A (en) Humanized antibodies targeting human tissue factor.
MX385284B (en) Monoclonal antibodies against the epidermal growth factor receptor (EGFR) for use in the treatment of patients diagnosed with pancreatic ductal adenocarcinoma.
PH12012500296A1 (en) Anti-angiogenesis therapy for the treatment of previously treated breast cancer
MX2014013763A (en) Dosage and administration of bispecific scfv conjugates in combination with anti-cancer therapeutics.